AR and posterior cortical atrophy: He et al., in an exhaustive review [52], reported the recent therapeutic advances in improving the clinical management of PCa patients, describing several chemicals targeting cell signalling or pathways associated with specific molecular alterations, in addition to AR-signalling inhibitors, representing the gold standard for the treatment of androgen-sensitive PCa forms.